Back

Discussant review - CARDINAL HF

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: medical therapy Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Allan Bohm

Premedix & Seerlinq, Bratislava (Slovakia)

9 More presentations in this session

Presentation thumbnail
A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
Professor C. Lam (Singapore, SG)
Slides Video
Presentation thumbnail
Discussant review - MIRACLE
Professor M. Packer (Dallas, US)
Slides Video
Presentation thumbnail
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
Professor J. Udelson (Boston, US)
Slides Video
Presentation thumbnail
Readily available urinary sodium analysis in patients with acute decompensate Heart Failure
Doctor E. Meekers (Genk, BE)
Slides Video
Presentation thumbnail
Discussant review - EASY-HF
Doctor P. Pellicori (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: medical therapy
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
thumbnail
Congress Presentation
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
thumbnail
ESC Journals
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources